Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 5/2012

01-10-2012

Improvements in Cystic Fibrosis Lung Disease and Airway Inflammation Associated with Etanercept Therapy for Rheumatoid Arthritis: A Case Report

Authors: S. Visser, M. Martin, D. J. Serisier

Published in: Lung | Issue 5/2012

Login to get access

Abstract

Cystic fibrosis (CF) lung pathology is characterized by excessive neutrophilic inflammation and high tumor necrosis factor-alpha (TNF-α) levels. A cornerstone of CF management is reduction of the inflammatory burden in the lung. We present the case of a 19-year-old CF patient who demonstrated significant clinical improvement in her lung disease associated with a reduction in sputum percent neutrophils, following commencement of etanercept (TNF-α antagonist) for rheumatoid arthritis. She has not had any infectious complications or other significant adverse effects during 2 years of treatment. It may be time to reconsider TNF-α antagonists as potential anti-inflammatory agents for CF lung disease.
Literature
1.
Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918–951PubMedCrossRef
2.
Cohen-Cymberknoh M, Shoseyov D, Kerem E (2011) Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183:1463–1471PubMedCrossRef
3.
Konstan MW, Doring G, Lands LC et al (2005) Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 40(Suppl 28):125
4.
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef
5.
Curtis JR, Xi J, Patkar N et al (2007) Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumour necrosis factor antagonists. Arthritis Rheum 56:4226PubMedCrossRef
6.
Casserly B, Donat W (2009) Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumour necrosis factor alpha. Lung 187:149–152PubMedCrossRef
7.
Vincenzi F, Bizzarri B, Ghiselli A, de Angelis N, Fornaroli F, de Angelis GL (2010) Cystic fibrosis and Crohn’s disease: successful treatment and long term remission with infliximab. World J Gastroenterol 16(15):1924–1927PubMedCrossRef
Metadata
Title
Improvements in Cystic Fibrosis Lung Disease and Airway Inflammation Associated with Etanercept Therapy for Rheumatoid Arthritis: A Case Report
Authors
S. Visser
M. Martin
D. J. Serisier
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Lung / Issue 5/2012
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-012-9393-9

Other articles of this Issue 5/2012

Lung 5/2012 Go to the issue

OriginalPaper

Effect of Smoking and Gender on Pulmonary Function and Clinical Features in Sarcoidosis

OriginalPaper

Sexual Dysfunction in Men with COPD: Impact on Quality of Life and Survival

OriginalPaper

Interferon γ Stimulates Accumulation of Gas Phase Nitric Oxide in Differentiated Cultures of Normal and Cystic Fibrosis Airway Epithelial Cells

ReviewPaper

The Utility of Interventional Pulmonary Procedures in Liberating Patients with Malignancy-Associated Central Airway Obstruction from Mechanical Ventilation

OriginalPaper

Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations

OriginalPaper

Response of Peripheral Blood Th17 Cells to Inhaled Dermatophagoides pteronyssinus in Patients with Allergic Rhinitis and Asthma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits